|Bid||7.79 x 1000|
|Ask||7.82 x 4000|
|Day's Range||7.67 - 7.94|
|52 Week Range||5.81 - 19.00|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.33|
If the high-water price target for each of the following five stocks were to come to fruition, shareholders would be looking at gains ranging from a low of 195% to as much as 467%. If you're "only" looking to triple your money, analyst Amit Dayal of H.C. Wainwright would suggest putting it to work in hydrogen fuel-cell solutions company Plug Power (NASDAQ: PLUG). Dayal's price target of $78 implies a cool 195% upside from where its shares closed this past weekend.
What happened Shares of Inovio Pharmaceuticals (NASDAQ: INO) were jumping 5.9% higher as of 11:07 a.m. EDT on Thursday after rising as much as 13.6% earlier in the session. The big gain came following Inovio's announcement that Brazilian regulators authorized the initiation of a phase 3 clinical study of COVID-19 vaccine candidate INO-4800.
Inovio Pharmaceuticals Inc said on Thursday it would start a large study for its experimental COVID-19 vaccine in the next few weeks, after the drugmaker received authorization from Brazil's regulatory agency. The company is currently working on importing the vaccine to Brazil and expects dosing of trial participants to begin in September, Chief Executive Officer Joseph Kim told Reuters. Inovio started developing its COVID-19 DNA vaccine, INO-4800, last year but fell behind rivals after the U.S. Food and Drug Administration (FDA) put the Phase 3 portion of its mid-to-late stage trial on hold for more information on the vaccine delivery device.